1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. ORPHAN DRUG MARKET BY DISEASE TYPE
5.1. Oncologic Disease
5.2. Metabolic Disease
5.3. Hematologic and Immunologic Disease
5.4. Infectious Disease
5.5. Neurologic Disease
5.6. Others
6. ORPHAN DRUG MARKET BY PRODUCT TYPE
6.1. Biological Products
6.2. Non-Biological Products
7. ORPHAN DRUG MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Others
7.2. South America
7.2.1. Brazil
7.2.2. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Investment Analysis
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Bayer
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. Amryt Pharma PLC
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Brisol-Myers Squibb Company
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Novartis AG
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. Celgene Corporation
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. F.Hoffman-La Roche AG
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Pfizer Inc.
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Alexion
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. Sanofi
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. AbbVie, Inc.
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
9.11. RegeneRX Biopharmaceuticals, Inc.
9.11.1. Company Overview
9.11.2. Financials
9.11.3. Products and Services
9.11.4. Recent Developments
9.12. Johnson & Johnson Services, Inc.
9.12.1. Company Overview
9.12.2. Financials
9.12.3. Products and Services
9.12.4. Recent Developments
9.13. Shire PLC
9.13.1. Company Overview
9.13.2. Financials
9.13.3. Products and Services
9.13.4. Recent Developments
9.14. Merck & Co. Inc.
9.14.1. Company Overview
9.14.2. Financials
9.14.3. Products and Services
9.14.4. Recent Developments
9.15. AstraZeneca
9.15.1. Company Overview
9.15.2. Financials
9.15.3. Products and Services
9.15.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES